Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Zhu reengineered the RSV F protein by changing a pair of molecules ... Sarah Auclair, Robyn L. Stanfield, Linling He, and Ian A. Wilson of Scripps. More information: Yi-Zong Lee et al, Rational ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Here’s what you need to know about the RSV vaccines and other types of immunization. Arexvy and Abrysio are protein-based vaccines that contain protein F, a surface protein from the RSV virus.

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

The two vaccines induce the immune system to target a critical protein on the surface of RSV, the F protein, in its pre-infection form, known as pre-fusion F. High levels of antibodies against pre ...

The trimeric pre-fusion glycoprotein F is essential for accurately assessing the immunogenicity of RSV vaccines. We strictly adhere to regulations to provide high-quality, consistent, native ...

BLB201 encodes the RSV F protein and uses a proprietary PIV5 vector, which is not known to cause human disease. PIV5 has been commonly administered to dogs as part of combination distemper/kennel ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of ...